MiMedx Group Inc (MDXG) had a good day on the market for Tuesday November 26 as shares jumped 6.46% to close at $6.43. About 1.68 million shares traded hands on 1,873 trades for the day, compared with an average daily volume of n/a shares out of a total float of 110.75 million. After opening the trading day at $6.07, shares of MiMedx Group Inc stayed within a range of $6.50 to $5.72.
With today’s gains, MiMedx Group Inc now has a market cap of $712.15 million. Shares of MiMedx Group Inc have been trading within a range of $6.37 and $0.95 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from human amniotic membrane and birth tissues and human skin and bone. Its products are primarily targeted toward the wound-care, surgical, sports medicine, and orthopedics markets. MiMedx’s key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. It also sells OrthoFlo, an allograft derived from amniotic fluid. In addition, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
MiMedx Group Inc is based out of Marietta, GA and has some 690 employees. Its CEO is Timothy R. Wright.
MiMedx Group Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.